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Abstract 
Increasing evidence indicates that native mu and delta opioid receptors can associate to form 
heteromers in discrete brain neuronal circuits. However, little is known about their signaling 
and trafficking. Using double fluorescent knock-in mice, we investigated the impact of 
neuronal co-expression on the internalization profile of mu and delta opioid receptors in 
primary hippocampal cultures and in vivo. We established ligand selective mu-delta co-
internalization upon activation by exogenous ligands and provide evidence for mu-delta co-
internalization by the endogenous opioid peptide met-enkephalin, but not β-endorphin. Co-
internalization was driven by the delta opioid receptor, required an active conformation of 
both receptors and led to sorting to the lysosomal compartment. This alteration in the mu 
opioid receptor intracellular fate was accompanied by sustained ERK1/2 phosphorylation. In 
addition, increased mu-delta neuronal co-localization in the rostral ventromedial medulla in a 
chronic neuropathic state suggests that mu-delta heteromers are involved in the regulation of 
nociceptive transmission 
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G protein-coupled receptors, opioid receptor, heteromers, internalization, ERK 
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Introduction 
The opioid system modulates numerous physiological functions such as nociception, 
emotional responses, reward and motivation, cognition but also neuroendocrine physiology 
and autonomic functions (Gaveriaux-Ruff and Kieffer 2002, Feng et al. 2012). The system is 
composed of three homologous G protein-coupled receptors (GPCR) mu, delta and kappa and 
three endogenous peptide families the enkephalins, endorphins and dynorphins. Several 
decades of opioid pharmacology have uncovered the physiological complexity of the system 
and highlighted functional interactions across receptors. Among these, molecular cross-talk 
between mu and delta opioid receptors have been extensively studied in co-transfected cells in 
which these two receptors can physically associate to form a novel entity with specific 
binding and signaling properties also called heteromer (Fujita et al. 2014). Evidence for mu-
delta receptor heteromers in vivo has also accumulated over the past years (Massotte 2015). 
Mapping mu and delta opioid receptors in the brain, spinal cord and dorsal root ganglia 
(DRG) using double fluorescent knock-in mice revealed discrete neuronal co-expression in 
subcortical networks essential for survival including the perception and processing of aversive 
stimuli with high mu-delta expression in the nociceptive pathways (Erbs et al. 2015). 
Moreover, electrophysiological data collected in the rostroventral medulla (RVM) established 
the presence of functional mu and delta opioid receptors in the same neurons (Pedersen et al. 
2011). Co-immunoprecipitation in the hippocampus (Erbs et al. 2015) or the spinal cord 
(Gomes et al. 2004) and high affinity for MDAN-21, a bivalent ligand bridging the mu 
agonist oxymorphone and the delta antagonist naltrindole, suggested that the two receptors 
are in close physical proximity (Daniels et al. 2005). Furthermore, direct structural contact 
could be disrupted in the brain, spinal cord and DRGs using interfering peptides (Xie et al. 
2009, He et al. 2011, Kabli et al. 2013). 
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Extensive literature established specific ligand binding properties, modification in 
signaling pathways and ligand selective opioid receptor co-internalization in heterologous 
systems (Fujita et al. 2014). However, our current knowledge of the ligand binding, signaling 
and trafficking properties of endogenous mu-delta heteromers in physiological and 
pathophysiological contexts remains fragmentary though crucial to understanding their 
functional relevance and to evaluating their physiological role(s) and potential as a therapeutic 
target. Devi’s research team showed cross-allosteric modulation with a positive cooperativity 
promoted upon binding of the first ligand in SKNSH neuroblastoma cells that naturally co-
express the two opioid receptors (Gomes et al. 2000, Gomes et al. 2004, Gomes et al. 2011). 
In VTA slices, co-application of the delta antagonist TIPPψ together with the mu agonist 
DAMGO or co-application of the mu antagonist CTAP together with the delta agonists 
deltorphin II or DPDPE strongly suggested that mu-delta receptor heteromerization decreases 
opioid signal transduction (Margolis et al. 2017). In addition, constitutive recruitment of β-
arrestin 2 by mu-delta heteromers was observed in SKNSH neuroblastoma cells that affected 
ERK1/2 signaling (Rozenfeld et al. 2007). Finally, the mu agonist DAMGO induced co-
internalization and co-recycling of mu and delta opioid receptors in DRG cultures pretreated 
with morphine, suggesting that mu-delta heteromerization may affect the trafficking of the 
delta opioid receptor in these conditions (Ong et al. 2015). However, further work is now 
needed to fully apprehend functional changes induced by mu-delta heteromerization, in 
particular upon activation by endogenous opioid peptides.  
In this context, we sought to better characterize the impact of mu-delta heteromerization 
on the intracellular fate of native mu and delta opioid receptors. We therefore took advantage 
of our double fluorescent knock-in mice co-expressing functional mu and delta opioid 
receptors respectively fused to the red fluorescent protein mCherry or the green fluorescent 
protein eGFP (Erbs et al. 2015) to monitor mu and delta receptor internalization in primary 
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hippocampal cultures or in vivo. We show ligand specific mu-delta receptor co-internalization 
induced by the mu-delta biased agonist CYM51010 (Gomes et al. 2013), but also the mu 
agonist DAMGO and the delta agonist deltorphin II. We also demonstrate that the mu-delta 
heteromer sorts to the lysosomal compartment. Using the double fluorescent mouse model, 
the activation of mu-delta heteromers by the endogenous opioid peptide Met-enkephalin 
modified the intracellular fate of the mu opioid receptor and produced sustained ERK1/2 
phosphorylation. Finally, we show that, in a pathological state of chronic pain, there is an 
increase in mu-delta receptor co-expression in the RVM, an important brain region involved 
in nociceptive transmission and regulation. Together, our data point to a specific 
physiological role of mu-delta heteromers and provide initial validation as novel therapeutic 
targets for innovative strategies in chronic pain management. 
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Material and methods  
Animals 
Double knock-in mice co-expressing fluorescent mu and delta opioid receptors (mu-
mCherry / delta-eGFP) were obtained by crossing previously generated single fluorescent 
knock-in mice expressing delta-eGFP or mu-mCherry, as described previously (Erbs et al. 
2015). Single fluorescent knock-in mice deficient for the other receptor were generated by 
crossing delta-eGFP with mu-knock-out mice or mu-mCherry with delta knock-out mice. The 
genetic background of all animals was 50:50 C57BL6/J:129svPas. Male and female adult 
mice (8 to 12 weeks old) were used for in vivo experiments. 
Mice were housed in an animal facility under controlled temperature (21 ± 2 °C) and 
humidity (45 ± 5 %) under a 12:12 dark–light cycle with food and water ad libitum. All 
experiments were performed in agreement with the European legislation (directive 
2010/63/EU acting on protection of laboratory animals) and received agreement from the 
French ministry (APAFIS 20 1503041113547 (APAFIS#300).02). 
 
Drugs 
D-Phe-Cys-Tyr-D-Trp-Pen-Thr-NH2 (CTAP) (C-6352), beta-funaltrexamine (β-FNA) (O-
003), fentanyl citrate (F3886), naltrindole (N-2893), [D-Ala2, NMe-Phe4, Gly-ol5]enkephalin 
(DAMGO) (E-7384), Met-enkephalin (H-2016), β-endorphin (E-6361), deltorphin II (T-
0658), and pertussis toxin (P-2980) were purchased from Sigma. (+)-4-[(αR)-α-((2S,5R)-4-
Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC80) (cat nº 
0764) was from Tocris bioscience, 1-[[4-(acetylamino)phenyl]methyl]-4-(2-phenylethyl)-4-
piperidinecarboxylic acid, ethyl ester (CYM51010) (ML-335) was from Cayman chemical 
and Tic-deltorphin was synthesized as reported in (Salvadori et al. 1999). 
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In vivo drug administration and sample preparation 
CYM51010 (10mg/kg), fentanyl (0.3mg/kg) and SNC80 (10mg/kg) were administered 
by i.p. injection. Met-enkephalin administration was performed by unilateral 
intracerebroventricular (icv) injection into the lateral ventricle of adult mice (3-4 months old) 
under general anasthesia. In brief, mice were anesthetized using ketamine/xylazine (100/10 
mg/kg, i.p.) and placed in a stereotaxic apparatus (David Kopf, Tujunga, CA). 5μL Met-
enkephalin 75mM was injected at coordinates: anteroposterior -0.2 mm, ±1 mm lateral -2mm 
dorsoventral. For opioid receptor phosphorylation, mice were sacrificed 30 minutes after drug 
administration, brains collected and immediately frozen in liquid nitrogen then kept at -80ºC 
until further use. For immunohistochemistry, mice were perfused at the indicated time points 
with cold paraformaldehyde 4% in phosphate buffer (PB) 0.1M pH 7.4 as described 
previously (Erbs et al. 2015). After 24 hours post-fixation, brain sections (30 μm thick) were 
cut with a vibratome (V1000 Leica) and kept floating in PB.     
 
Receptor phosphorylation 
Frozen brain samples were transferred into ice-cold detergent buffer (50 mM Tris-HCL, 
pH 7.4; 150 mM NaCl; 5 mM EDTA; 10 mM NaF; 10 mM disodium pyrophosphate; 1% 
Nonidet P-40; 0.5% sodium deoxycholate; 0.1% SDS; containing protease and phosphatase 
inhibitors) and homogenized using MINILYS workplace homogenizer (Peqlab; Erlangen, 
Germany). Tissue homogenates were centrifuged at 16000 × g for 30 min at 4 °C after 1 h 
lysis at 4 °C. For the immunoprecipitation of mouse delta-eGFP or muP-mCherry, anti-GFP 
beads or anti-RFP beads (NanoTag; Goettingen, Germany) were used. The tissue supernatant 
were incubated with the beads for 2 h at 4 °C and proteins were eluted from the beads with 
SDS-sample buffer for 30 min at 50 °C. Proteins were separated on 7.5% SDS-
polyacrylamide gels and after electroblotting, membranes were incubated with anti-pS363 
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(Assay Biotechnology Company Inc; CA, USA), anti-pT370, anti-S375, anti-T376 or anti-
T379 antibodies at a concentration of 0.1 µg/ml and detected by chemiluminescence with 
ECL according to the manufacturer instructions (Doll et al. 2011, Just et al. 2013) . To 
confirm equal loading of the gels, blots were stripped and re-probed with the phosphorylation-
independent anti-GFP antibody (Synaptic Systems; Goettingen, Germany) or anti-RFP 
(ChromoTek GmbH; Planegg-Martinsried, Germany).  
 
Primary neuronal culture  
Primary neuronal cultures were performed as previously described (Derouiche et al. 
2018). Briefly, P0-P3 mice pups were decapitated, hippocampi were dissected and digested 
with papain (20 U/mL,Worthington  cat. no. LS003126). Cells were plated (8-10x104 
cells/well) on poly-lysine (PLL, Sigma) coated coverslips in 24-well plates for 
immunofluorescence studies or in 12-well plates coated with poly-lysine for ERK 
phosphorylation studies. Cultures were maintained for 15 days in vitro (DIV) with half of the 
medium (Neurobasal A medium supplemented with 2% B27 (GIBCO, cat. no. 17504044), 
2mM glutamax (GIBCO, cat. no. 35050061), 0.5mM glutamine and penicillin/streptomycin) 
changed every 5-7 days. Fully matured primary neurons (DIV 10 to 14) were used for all 
studies. 
 
Ex vivo drug administration and sample preparation 
Met-enkephalin, β-endorphin, DAMGO, naltrindole, CTAP, deltorphin II and Tic-
deltorphin were dissolved in sterile milliQ water, CYM51010 was dissolved in saline solution 
with DMSO (0.2% final volume) and Tween 80 (1% final volume), SNC 80 was dissolved in 
DMSO at 10mg/ml. Drugs were added to the culture medium of mature neurons (as 1% of the 
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total culture volume) (12 to 15 days in vitro) and incubated at 37° C as indicated. Antagonists 
were added to the culture medium 15 minutes before agonist treatment.  
For immunofluorescence studies, cultures were washed in cold 0.1 M saline phosphate 
buffer pH 7.4 (PBS) and fixed with 4% Paraformaldehyde in PBS.  Cells were washed 3 times 
with cold PBS and kept at 4°C until processing.  
For Western blot analyses, the medium cells were directly harvested at the end of the 
drug treatment in cold 100 μL/well Laemmli buffer. Cell lysates were incubated for 5 minutes 
at 95°C and kept at -20°C until further use.  
 
ERK1/2 phosphorylation  
For each condition, 15 μL of sample were separated on 12% SDS-PAGE and 
transferred to PVDF membranes (Immobilon, Millipore). Following blocking in 5% non-fat 
dry milk in 50mM Tris-HCl pH8, 150mM NaCl, 0.5 % Tween 20 (TBST), membranes were 
incubated overnight at 4ºC with monoclonal mouse mAb anti-phospho-p44/42MAPK (anti-
pERK; 1:3000; Cell Signaling #9106) in blocking buffer, washed 3 times in TBST and 
incubated for 2 hours at room temperature with a goat anti-mouse HRP-conjugated secondary 
antibody (Molecular Probes, cat. n° 3412). Chemiluminescence was detected using ECLTM 
Prime Western Blotting Detection Reagent (Amersham Biosciences, cat. n° RPN2232) 
according to the manufacturer instructions. Following detection of the phosphorylated ERK 
forms, membranes were stripped in 100mM Glycine buffer pH 2.6 for 1h at room temperature 
and processed as described above for total MAPK detection with a polyclonal rabbit antibody 
anti-p44/42MAPK (anti-ERK1/2; 1:5000 Cell signaling, cat nº 9102) followed by goat anti-
rabbit HRP-conjugated secondary antibody (1:10.000, Millipore, cat nº AP307P). For each 
time point, the density of ERK 1/2 phosphorylation was normalized to the density of total 
ERK using the ImageJ software. 
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Fluorescent detection with antibodies  
Primary neuronal cultures or brain section were incubated in the blocking solution 
PBST (PBS with 0.2 % Tween 20 (Sigma)) and 5 % normal goat serum (Sigma)) for one hour 
at room temperature (20-22°C) and then in primary antibodies (table 1) diluted in the 
blocking solution overnight at 4°C. Cells were washed three times in PBST and incubated for 
two hours with the secondary antibodies diluted in blocking solution (table 1). After three 
washes in PBST, nuclei were stained with DAPI (1µg/mL in PBS) for 5 minutes. Samples 
were mounted with ProLong™ Gold Antifade mounting medium (Molecular Probes) and kept 
at -20° protected from light until confocal imaging.   
 
Mu-delta neuronal co-expression in the rostroventral medulla 
Neuropathic pain was induced in double fluorescent knock-in mice by cuffing the main 
branch of the right sciatic nerve as previously described (Benbouzid et al. 2008, Yalcin et al. 
2014). Surgeries were performed under ketamine (Vibrac, Carros, France) / xylazine 
(Rompun, Kiel, Germany) anesthesia (100/10mg/kg, i.p.) on male and female mice. The 
common branch of the right sciatic nerve was exposed, and a cuff of PE-20 polyethylene 
tubing (Harvard Apparatus, Les Ulis, France) of standardized length (2mm) was unilaterally 
inserted around it (Cuff group). Sham-operated animals underwent the same surgical 
procedure without cuff implantation (Sham group). Mice were perfused 8 weeks later with 
cold paraformaldehyde 4% in PB 0.1M pH 7.4 as described previously (Erbs et al. 2015). 
After 24 hours post-fixation, brain were cryoprotected and sections (30 μm thick) cut with a 
cryostat (Microm Cryo-star HM560) and kept floating in PB for immunohistochemistry.  
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Image acquisition and analysis 
Confocal images were acquired (Leica SP5) using a 63x (NA 1.4) oil immersion 
objective and analyzed with ICY software (http://icy.bioimageanalysis.org/) as previously 
described (Derouiche et al. 2018). Briefly, quantification was performed on a single plane 
image from a z-stack within two sequential steps. First, the plasma membrane and 
cytoplasmic compartment were defined for each neuron. The spots were then detected in each 
channel and the amount of co-localization determined in each region of interest. The protocol 
used in these analyses is available online (NewColocalizer with binary and excel output 
v1_batch.xml). The extent of internalization is expressed as the ratio of membrane/cytoplasm 
immunoreactivity densities for each receptor or co-localized mu-delta. Co-localization of the 
two receptors is expressed as the percentage of co-localized mu-mCherry and delta-eGFP 
signals reported to the total immunoreactivity.  
Quantification of neurons co-expressing mu and delta opioid receptors in the 
rostroventral medulla was performed using the NDP view plus software (Hamamatsu 
Photonics) on images from at least 5 non consecutive sections (bregma -5.5 to -6.5) on areas 
including the posterior raphe nuclei (pallidus, magnus, obscurus, interpositus), the 
parapyramidal nucleus, the alpha part of the gigantocellulat reticular nucleus and lateral 
paragigantocellular nucleus according to the Paxinos atlas v4. 
 
Statistical analysis 
Statistical analyses were performed with Graphpad Prism V7 software (GraphPad, San 
Diego, CA). Normality of the distributions and homogeneity of the variances were checked 
before statistical comparison to determine appropriate tests. One-way non-parametric 
(Kruskal Wallis followed by Dunn’s multiple comparison test) or parametric one-way 
ANOVA test (followed by Dunnett’s multiple comparison test) were used to compare 
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different experimental groups. A two-way ANOVA followed by post-hoc Tukey’s test for 
multiple comparisons was used for multiple factor comparisons. Results in graphs and 
histograms are illustrated as means ± SEM.  
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Results  
Endogenous mu-delta heteromers are present at the neuronal surface under basal 
conditions. 
Previous work showed receptor expression at the surface of hippocampal neurons in 
basal conditions of the fluorescent knock-in mice expressing delta-eGFP and/or mu-mCherry 
(Scherrer 2006; Pradhan 2010;Faget 2012; Erbs 2014; Erbs 2015). As expected, under basal 
conditions, both mu and delta opioid receptors were predominantly located at the plasma 
membrane in primary hippocampal neurons as revealed by confocal imaging of mu-mCherry 
and delta-eGFP associated fluorescence (Figure 1A left panel). Quantification of the receptor 
density using the ICY bioimaging software (Derouiche et al. 2018) indicated that the 
fluorescence density at the cell surface was 2.5-fold higher compared to the cytoplasm for 
either receptor (Figure 1B). Merged images highlighted an overlay of the green and red 
fluorescence at the surface of the neuron and quantification of the density of receptor co-
localization indicated about 20% of the total mu-mCherry or delta-eGFP signals co-localized 
at the plasma membrane (Figure 1C) and only 10% of the receptors co-localized in the 
cytoplasm (Figure 1D; see also Figure S1). Data therefore establish close physical proximity 
of endogenous mu and delta opioid receptors at the plasma membrane under basal conditions 
and suggest constitutive mu-delta heteromerization at the surface of neurons.  
 
CYM51010 induces mu-delta receptor co-internalization and co-localization in the 
late endosomal compartment 
CYM51010 was reported as a mu-delta biased agonist because its antinociceptive effect 
was blocked by an antibody selective for mu-delta heteromers and its activity was reduced in 
mice deficient for the mu or delta opioid receptor (Gomes et al. 2013). We therefore tested 
whether activation by this ligand (concentration range 10nM to 10μM) triggered mu and delta 
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receptor internalization in primary hippocampal cultures from double fluorescent knock-in 
mice. CYM51010 concentrations equivalent to, or higher than, 400nM induced mu-mCherry 
and delta-eGFP internalization as seen from the decrease in fluorescence density associated 
with the plasma membrane and the appearance of fluorescent intracellular vesicles (Figure 
1A middle and right panels, Figure 1B). Quantification of the extent of co-localization 15, 
30 and 60 minutes after agonist administration showed that the fraction of mu and delta 
opioid receptors that co-localized at the plasma membrane significantly decreased (Figure 
1C) whereas mu-delta receptor co-localization increased in the cytoplasm at the three time 
points (Figure 1D) establishing co-internalization of the receptors. Triple 
immunofluorescence labeling with LAMP1 as a marker of the late endosomal-lysosomal 
compartment showed increased co-localization with mu-mCherry and delta-eGFP 60 minutes 
after activation by CYM51010 (Figure 2) suggesting that mu and delta opioid receptors are 
targeted together to the degradation pathway. 
We then sought to investigate whether internalization of the mu opioid receptor by 
CYM51010 was promoted by its association with the delta opioid receptor. In primary 
hippocampal cultures from single fluorescent knock-in animals expressing mu-mCherry and 
deficient for the delta opioid receptor, CYM51010 concentrations up to 1μM failed to induce 
mu-mCherry internalization (Figure 3A-B) with only limited mu opioid receptor clustering 
and subcellular redistribution at 10μM (Figure 3B). In contrast, the mu selective agonist 
DAMGO 1μM induced strong internalization of mu-mCherry (see also Figure S2) 
confirming the ability of this ligand to induce endogenous mu opioid receptor internalization 
(Trafton et al. 2000, Erbs et al. 2015).  
We then examined whether internalization of the delta opioid receptor upon activation 
by CYM51010 required mu opioid receptor co-expression. In primary hippocampal cultures 
from single fluorescent knock-in animals expressing delta-eGFP and deficient for the mu 
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opioid receptor, CYM51010 (400nM) induced internalization of the delta opioid receptor 
(Figure 3C). In addition, predominant intracellular localization was observed 30 and 60 
minutes after agonist application (Figure 3D) in agreement with kinetics described for the 
delta selective agonist SNC80 (Scherrer et al. 2006, Pradhan et al. 2009, Faget et al. 2012)) 
indicating that CYM51010 was able to promote delta opioid receptor internalization despite 
the lack of mu opioid receptor expression.  
Together, this data establishes that mu opioid receptor internalization by CYM51010 is 
dependent on mu-delta receptor co-expression and directs the mu opioid receptor to the late 
endocytic compartment.  
 
CYM51010 induced mu-delta receptor co-internalization is blocked by pretreatment 
with mu or delta selective antagonists  
In neurons expressing one receptor only, CYM51010 activation led to the 
internalization of delta but not mu opioid receptors (Figure 3). We therefore sought to 
determine whether co-internalization by CYM51010 required the two receptors to be in an 
active conformation.  To this aim, we examined the impact of pre-treatment for 15 minutes 
with the mu selective antagonists β-FNA (20nM) or CTAP (200nM). Both antagonists 
prevented mu opioid receptor cellular redistribution but did not block delta opioid receptor 
internalization (Figure 4A, C-D). These results suggest that an active conformation of the mu 
opioid receptor is required for mu-delta co-internalization. 
We then evaluated the need for delta opioid receptor activation in the co-internalization 
process. Whereas pre-treatment with mu antagonists blocked mu but not delta opioid receptor 
internalization, pre-treatment with the selective delta antagonists naltrindole or Tic-deltorphin 
200 nM blocked the internalization of both delta and mu opioid receptors (Figure 4B-D).  
This indicates that mu-delta cellular redistribution is driven by delta opioid receptor 
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expression and activation. Together, this data indicates that mu-delta receptor co-
internalization upon CYM 51010 activation is driven by delta opioid receptors and requires 
both mu and delta opioid receptors to be in an active conformation.  
 
 CYM51010 induces phosphorylation of mu and delta opioid receptors  
To confirm that active conformation of the receptors is required for internalization, we 
also examined the phosphorylation profile of mu and delta opioid receptors in vivo in 
response to CYM51010 (10mg/kg i.p.) using antibodies for the different phosphorylation sites 
on the receptors. The mu-delta agonist induced phosphorylation of the serine residue S363, 
the primary site of the delta opioid receptor whether the receptor was expressed alone (delta-
eGFP/mu KO mouse) or together with the mu opioid receptor (mu-mCherry/ delta-eGFP 
mouse) (Figure 5A). This result is similar to the phosphorylation following activation by the 
delta selective agonist SNC80 (Figure 5A). CYM51010 also promoted phosphorylation at the 
primary mu opioid receptor phosphorylation site serine S375 and at threonine residues T370, 
T376, T379 whether the mu opioid receptor was expressed alone (mu-mCherry/delta KO 
mouse) or together with the delta opioid receptor (mu-mCherry/ delta-eGFP mouse). The 
phosphorylation profile was similar to the one observed following activation with the mu 
selective agonist fentanyl (0.3mg/kg i.p.) (Figure 5B).  
Together, this data indicates that mu-delta receptor co-internalization upon CYM 51010 
requires phosphorylation of both mu and delta opioid receptors.  
 
Mu-delta receptor co-internalization is ligand specific 
We then examined whether other synthetic opioid agonists were able to promote mu-
delta receptor co-internalization in primary hippocampal cultures. Mu-delta receptor co-
localization in the cytoplasm was increased 30 minutes after stimulation with the mu agonist 
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DAMGO (1μM) or the delta agonist deltorphin II (100nM) but not upon stimulation with the 
delta agonist SNC 80 (Figure 6). These data establish ligand specific internalization of 
endogenous mu-delta heteromers by exogenous opioids. 
 
Met-enkephalin induced mu-delta co-internalization and co-localization in the late 
endosomal compartment 
The endogenous opioid peptide met-enkephalin promotes internalization and fast 
recycling to the plasma membrane of mu opioid receptors (Trafton et al. 2000, Minnis et al. 
2003) as well as internalization and subsequent lysosomal degradation of the delta opioid 
receptor (Scherrer et al. 2006, Pradhan et al. 2009). Accordingly, in primary hippocampal 
cultures from single fluorescent knock-in mice expressing mu-mCherry and deficient for the 
delta opioid receptor, activation with met-enkephalin 100nM led to mu-mCherry predominant 
intracellular localization 30 minutes after agonist application. After 60 minutes, mu-mCherry 
was detected at the plasma membrane consistent with the kinetics of a fast recycling receptor 
(Figure 7A, B). In contrast, in primary hippocampal cultures from single fluorescent knock-in 
mice expressing delta-eGFP and deficient for the mu opioid receptor, the receptor was mainly 
located in the cytoplasm at both time points following activation with met-enkephalin 100nM 
consistent with the kinetics of a receptor type that is degraded upon internalization (Figure 
7C, D).  
We then examined whether met-enkephalin also promoted mu-delta receptor co-
internalization and modified the mu opioid receptor intracellular fate. Met-enkephalin 
(100nM) application for 15, 30 or 60 minutes was associated with reduced fluorescence at the 
cell surface and led to the redistribution of both mu-mCherry and delta-eGFP signals in 
cytoplasmic vesicular structures (Figure 8A, B). Importantly, the percentage of mu-delta 
heteromers also decreased at the cell surface and increased intracellularly at the three time 
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points (Figure 8C) with significant increase in mu-delta heteromers at 60 minutes (Fig. 8D). 
At this time point, both mu and delta opioid receptors co-localized with the late endosomal-
lysosomal marker LAMP1 (Figure 9). 
Our results therefore suggest that mu and delta opioid receptors are targeted together to 
the degradation pathway as observed upon activation with CYM51010. They also establish 
that the endogenous opioid peptide met-enkephalin shifts the mu opioid receptor intracellular 
fate from the fast recycling to the degradation mode upon mu-delta heteromerization.  
 
Met-enkephalin induced mu-delta receptor co-internalization is blocked by 
pretreatment with mu or delta selective antagonists  
We then examined the impact of mu or delta selective antagonists on mu-delta receptor 
co-internalization in response to met-enkephalin. A 15 minutes pre-treatment with the mu 
selective antagonists CTAP or β-FNA prevented changes in the mu opioid receptor 
subcellular distribution with mu-mCherry fluorescence predominantly remaining visible at the 
plasma membrane (Figure 10A). In contrast, delta-eGFP was internalized and detected in 
intracellular vesicles after 60 minutes (Figure 10B). Pre-treatment with the mu antagonists 
thus prevented co-internalization indicating that the mu opioid receptor needs to be in an 
active form to be co-internalized with the delta opioid receptor (Figure 10C, D). Pre-
treatment with the delta selective antagonists naltrindole or Tic-deltorphin prevented delta 
opioid receptor internalization but also blocked mu opioid receptor subcellular redistribution 
indicating that the delta opioid receptor acted as the driver of the co-internalization (Figure 
10B-D). Similarly, pre-treatment with pertussis toxin (100ng/ml) for 24 hours, known to 
promote receptor uncoupling from inhibitory Gi/o proteins through ADP ribosylation of the 
Gα subunit, also prevented mu-delta co-internalization (see Figure S3). 
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Data indicates that mu-delta co-internalization following met-enkephalin activation 
involves active conformations of both receptors similar to that produced by CYM51010. 
Met-enkephalin induces mu-delta receptor co-internalization and co-localization in 
the late endosomal compartment in vivo 
We then examined the in vivo intracellular fate of mu-delta heteromers in response to 
met-enkephalin administration (375 nmoles i.c.v.). Under basal conditions, mu and delta 
opioid receptors were predominantly located at the plasma membrane (Figure 11A, B) with 
about 15% of mu and delta opioid receptors co-localized (Figure 11C), suggesting mu-delta 
heteromerization at the neuronal surface. These values were very similar to those collected in 
primary hippocampal cultures (Figure 1, see also Figure S1). Met-enkephalin administration 
led to the sequestration of both mu and delta opioid receptors (Figure 11A, B) and maintained 
the extent of receptor co-localization in the cytoplasm (Figure 11C). In addition, mu and 
delta opioid receptors co-localized with the late endosomal-lysosomal LAMP1 marker 60 
minutes after met-enkephalin administration, indicative of mu-delta receptor co-
internalization (Figure 11D).  
Endogenous mu-delta heteromers are thus present at the plasma membrane in vivo and 
undergo similar intracellular fate in the hippocampal tissue or in primary hippocampal 
cultures. 
 
Met-enkephalin induces phosphorylation of mu and delta opioid receptors  
To confirm activation of either receptor, we examined their phosphorylation profile 
following met-enkephalin activation in vivo (375 nmoles i.c.v.). Strong phosphorylation of the 
serine residue S363 was observed whether the receptor was expressed alone (delta-eGFP/mu 
KO mouse) or together with the mu opioid receptor (mu-mCherry/ delta-eGFP mouse) 
(Figure 5A). Similarly, robust phosphorylation at residues S375, T370, T376 and T379 was 
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observed whether the mu opioid receptor was expressed alone (mu-mCherry/delta KO mouse) 
or together with the delta opioid receptor (mu-mCherry/ delta-eGFP mouse) (Figure 5B).  
Together, data indicates that internalization of mu-delta heteromers following met-
enkephalin activation requires delta opioid receptors and involves active conformations of 
both receptors similar to that produced by CYM51010. Together, this data indicates that mu-
delta receptor co-internalization induced by met-enkephalin requires phosphorylation of both 
mu and delta opioid receptors as shown for co-internalization induced by the mu-delta biased 
agonist CYM51010.  
 
β-endorphin does not promote mu-delta opioid receptor co-internalization 
We then investigated the internalization profile of mu and delta opioid receptors upon 
activation by β-endorphin in primary hippocampal cultures. We observed a strong decrease of 
the delta-eGFP signal at the plasma membrane that persisted for at least 60 minutes after β-
endorphin (100nM) application in agreement with the slow recycling mode of the delta opioid 
receptor (Figure 12A, B). In contrast, changes in the mu-mCherry fluorescence associated 
with the plasma membrane were transient with a strong decrease in the signal after 15 minutes 
followed by partial recovery at 30 and 60 minutes as expected for fast receptor recycling to 
the plasma membrane (Figure 12A, B). Clear segregation of mu-mCherry and delta-eGFP 
signals was observed (Figure 12A). The density of mu–delta heteromer at the plasma 
membrane was not statistically significantly decreased at the 15 minute time point (Figure 
12C) and the density of intracellular mu-delta heteromers did not increase over time (Figure 
12D).  
Together, this data establishes that stimulation with β-endorphin does not induce co-
trafficking of mu and delta opioid receptors but rather each receptor maintains its respective 
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fast and low recycling modes. Unlike met-enkephalin, β-endorphin does not alter the mu 
opioid receptor intracellular fate through mu-delta heteromer activation.  
 
The kinetics of Met-enkephalin induced ERK1/2 phosphorylation is altered by mu-
delta heteromerization. 
Mu opioid agonists promote rapid and transient ERK1/2 phosphorylation via activation 
of the G protein dependent pathway (Massotte et al. 2002). Heteromerization of mu-delta 
opioid receptors in co-transfected CHO cells shifted ERK1/2 phosphorylation towards a later 
and more sustained profile following DAMGO stimulation (Rozenfeld and Devi 2007). Using 
the SKNSH cell line co-expressing endogenous mu and delta opioid receptors, the authors 
also showed that this profile was β-arrestin 2 dependent (Rozenfeld and Devi 2007). We 
therefore investigated whether mu-delta heteromerization also affected the kinetics of ERK1/2 
phosphorylation in primary hippocampal neurons. As expected, DAMGO (1μM) induced 
robust increase in ERK1/2 phosphorylation that lasted for 10 minutes before slowly going 
back to basal levels after 20 minutes (Figure 13A). Activation by the mu-delta biased agonist 
CYM51010 (400nM) led to a rapid 50% increase in ERK1/2 phosphorylation that lasted for 
15 minutes before returning to baseline (Figure 13A), consistent with its ability to recruit β-
arrestins (Gomes et al. 2013). We then examined ERK1/2 phosphorylation following 
activation by endogenous opioid peptides. Activation by β-endorphin (100nM) was slower 
compared to the other ligands tested and led to 40% increase in ERK1/2 phosphorylation 5 
minutes after stimulation before slowly returning to baseline levels at 20 minutes (Figure 
13A). Remarkably, met-enkephalin (100nM) induced a biphasic phosphorylation kinetics 
with a rapid transient 50% increase in phosphorylation after 3 minutes followed by a stronger 
and sustained phase that persisted for up to 20 minutes (Figure 13A). This data indicates that 
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activation of mu-delta heteromer by all four ligands promoted ERK1/2 phosphorylation but 
met-enkephalin only showed biphasic kinetics. 
We next verified that the strong long-lasting ERK1/2 phosphorylation was indeed 
specific to mu-delta heteromer activation by pretreating the culture with the mu antagonist 
CTAP (200nM) or the delta antagonist naltrindole (200nM). As expected, only transient 
phosphorylation was observed in both cases (Fig. 13B). In addition, pre-treatment with 
naltrindole increased the level of phosphorylation (about 130%) at the short time point 
(Figure 13B).   
Together, our data highlight sustained ERK1/2 phosphorylation by mu-delta heteromers 
in response to met-enkephalin and suggest spatio-temporal alteration in mu opioid receptor 
signaling.  
 
Mu-delta heteromerization is increased in the RVM of neuropathic animals.  
 We have previously identified mu-delta heteromers in the RVM using mu-
mCherry/delta-eGFP double fluorescent mice (Erbs et al. 2015). Since this region plays a key 
role in the control of the nociceptive descending pathway and is enkephalinergic (see also 
Figure S4), we examined whether the expression mu-delta heteromers is changed in 
neuropathic pain conditions induced by sciatic nerve injury. Indeed, the number of neurons 
co-expressing mu-delta almost doubled in neuropathic pain animals (91 ± 9 vs 47 ± 4 
neurons/mm2, unpaired Student’s t test, p value=0.0097) (Figure 14) pointing to potential 
mu-delta modulation of the nociceptive response in this pathological condition. 
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Discussion  
Using double fluorescent knock-in mice, we investigated the impact of heteromerization 
on the internalization of endogenous mu and delta opioid receptors. We first established 
ligand selective co-internalization upon activation by CYM51010, DAMGO and deltorphin II 
but not SNC80. We then evidenced mu-delta co-internalization upon activation by the 
endogenous opioid peptide met-enkephalin but not β-endorphin. Co-internalization was 
driven by the delta opioid receptor, required an active conformation of both mu and delta 
opioid receptors and led to sorting to the lysosomal compartment. Altered mu opioid receptor 
intracellular fate and sustained ERK1/2 phosphorylation were observed in response to met-
enkephalin. Moreover, increased expression of mu-delta heteromers was detected in the RVM 
under neuropathic conditions, strongly suggesting a role in the control of the descending 
nociceptive pathway.  
 
Internalization of endogenous mu-delta heteromers is ligand selective 
In primary hippocampal cultures, endogenous mu-delta opioid receptors co-internalized 
in response to CYM51010, DAMGO or deltorphin II, but not in response to SNC80 indicating 
ligand specificity. In co-transfected HEK293 cells, co-internalization of mu and delta opioid 
receptors was reported following activation by the mu agonists DAMGO (Hasbi et al. 2007, 
Kabli et al. 2010, He et al. 2011) or methadone (Milan-Lobo and Whistler 2011) or following 
activation by the delta agonists SNC80 (Kabli et al. 2010, He et al. 2011), UFP512 (Kabli et 
al. 2010), deltorphin I (He et al. 2011), deltorphin II (Hasbi et al. 2007, Kabli et al. 2010, He 
et al. 2011) or DPDPE (Kabli et al. 2010). Differences between native and heterologously 
expressed receptors may reflect distinct cellular contents (Benredjem et al. 2017). Indeed, no 
mu-delta receptor co-internalization is detected in the spinal cord following SNC80 (10mg/kg 
i.p.) administration (Wang et al. 2018). Also, internalization of the delta opioid receptor is 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/455147doi: bioRxiv preprint first posted online Oct. 28, 2018; 
 24
dependent on GRK2 in cortical neurons but not in transfected HEK 293 cells although the 
latter express GRK2 and support GRK2 mediated internalization of other GPCRs (Charfi et 
al. 2014). Similarly, the ability of ligands to differentially activate signaling pathways in 
AtT20 neuroblastoma and CHO cell lines uncovers clear influence of the cellular background 
on mu opioid receptor signaling (Thompson et al. 2016). Moreover, mu opioid receptor 
internalization in response to morphine only takes place in selected neuronal types indicating 
that variations among neuronal populations also exist. (Haberstock-Debic et al. 2005). 
Finally, high expression levels of a GPCR in a non-native environment can also artificially 
elicit interactions that would not occur in vivo and subsequently affect functional responses.  
A potential influence of the fluorescent tag on the receptor subcellular distribution is 
also to be considered. In particular, strong surface expression of the delta-eGFP construct in 
the hippocampus could alter receptor trafficking and signaling. However, no overt change in 
the neuroanatomical distribution, pharmacological and signaling properties or behavioral 
response has been evidenced so far in the knock-in mice expressing the delta-eGFP and/or 
mu-mcherry fluorescent fusions (reviewed in (Ceredig and Massotte 2014). Importantly, 
delta-eGFP surface expression varies across the nervous system and is increased upon chronic 
morphine administration (Erbs et al. 2016) or in neuropathic pain conditions (Ceredig et al. 
2018) as previously reported for wild type receptors (reviewed in (Gendron et al. 2015), 
(Ceredig and Massotte 2014). Moreover, the use of the delta-eGFP fusion enabled to detect in 
vivo partial receptor internalization in response to a physiological stimulation (Faget et al. 
2012). The fluorescent knock-in mice therefore appear well suited reporters for native opioid 
receptor studies.  
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Internalization of endogenous mu-delta heteromers requires both receptors in an 
active conformation  
Phosphorylation of the delta opioid receptor C–terminus is important for agonist-
induced β-arrestin 2 recruitment (Qiu et al. 2007) and mu opioid receptor phosphorylation 
facilitates endocytosis through enhanced receptor affinity for β-arrestin (Qiu et al. 2003). In 
co-transfected HEK293 cells, mu-delta receptor co-internalization by the delta agonists SNC 
80 and deltorphin I or the mu agonist DAMGO is correlated to increased phosphorylation at 
the delta or the mu opioid receptor respectively (He et al. 2011). Moreover, the mu opioid 
receptor is not internalized following stimulation by the delta selective agonists SNC 80 or 
deltorphin I when co-expressed with a phosphorylation deficient delta opioid receptor (He et 
al. 2011). These results indicate that activation of the delta opioid receptor is required to 
promote co-internalization of the mu opioid receptor by delta agonists. Here, we show that 
both mu and delta opioid receptors are phosphorylated when activated by the biased mu-delta 
agonist CYM51010 or by the endogenous opioid peptide met-enkephalin. Both ligands 
promote phosphorylation at the serine S363 residue which is required for delta opioid receptor 
internalization by exogenous agonists in HEK293 cells (Kouhen et al. 2000, Law et al. 2000) 
and is also phosphorylated in vivo upon activation with met-enkephalin (Faget et al. 2012). 
Both ligands also increase phosphorylation at serine S375 and threonine T370, T376 and 
T379 residues necessary for mu opioid receptor internalization by exogenous ligands such as 
DAMGO and fentanyl or by the endogenous opioid peptide met-enkephalin (Just et al. 2013, 
Yousuf et al. 2015). Endogenous mu-delta receptor co-internalization is blocked by mu 
(CTAP, cyprodime, β-FNA) or delta (naltrindole, tic-deltorphin) selective antagonists. In co-
transfected HEK 293 cells, the mu agonist CTOP blocked mu-delta receptor co-internalization 
by the delta agonists UFP512, SNC80 or deltorphin II whereas the delta antagonist naltrindole 
reduced mu-delta receptor co-internalization by the mu agonist DAMGO (Kabli et al. 2010). 
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Moreover, internalization of the mu opioid receptor was not observed upon mu-delta receptor 
co-transfection in the absence of a ligand despite detection of delta constitutive internalization 
(Law et al. 2005). In addition, pre-treatment with pertussis toxin in primary hippocampal 
neurons blocked DAMGO induced mu-delta co-internalization supporting the need for a G 
protein activatable conformation of the mu opioid receptor. Co-internalization thus requires 
that both mu and delta opioid receptors are in an active conformation. 
Interestingly, delta antagonists blocked mu-delta receptor co-internalization whereas mu 
antagonists only blocked mu opioid receptor internalization without affecting delta opioid 
receptor internalization and degradation. These data indicate that the delta opioid receptor is 
driving the co-internalization, possibly through constitutive interaction with β-arrestin (Law 
et al. 2000, Bradbury et al. 2009). Delta antagonists could therefore inhibit co-sequestration of 
the receptors by destabilizing this interaction and inducing dissociation from the heteromer as 
previously proposed (Rozenfeld and Devi 2007). 
 
The intracellular fate of mu opioid receptors is altered by mu-delta heteromerization 
in vivo 
Mu opioid receptors rapidly recycle back to the plasma membrane in vivo (Trafton et al. 
2000). Endogenous delta opioid receptors, in contrast are slow recycling receptors that are 
degraded in the lysosomal compartments (Pradhan et al. 2009). Here, we observe that 
endogenous mu-delta heteromers are targeted to the lysosomal compartment in primary 
neurons and in vivo triggering a change in the mu opioid receptor intracellular fate following 
activation by exogenous or endogenous ligands. Noteworthy, this change does not correlate 
with differences in the receptor phosphorylation profile suggesting that it does not determine 
receptor recycling or degradation. Ubiquitination controls the endocytic trafficking and 
sorting from the endosomal membrane to the luminal compartment in multivesicular bodies 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/455147doi: bioRxiv preprint first posted online Oct. 28, 2018; 
 27
for a number of GPCRs (Skieterska et al. 2017). In co-transfected HEK293 cells, He et al (He 
et al. 2011) correlated deltorphin I ability to increase receptor ubiquitination with enhanced 
mu-delta receptor co-localization in the lysosomal compartment. However, this modification 
is not essential to determine the delta opioid receptor intracellular fate (Hislop et al. 2009, 
Henry et al. 2011) and is not involved in the targeting of mu opioid receptors to the recycling 
pathway though it is required for mu opioid receptor lysosomal down-regulation by ESCRT 
(endosomal sorting complex required for transport) (Henry et al. 2011). Mu opioid receptor 
endocytic trafficking between recycling and lysosomal pathways is rather regulated by the C-
terminal sequence LENLEAE called mu opioid regulatory sequence (MRS) (Tanowitz and 
von Zastrow 2003). Accordingly, mu opioid receptor splice variants lacking this sequence fail 
to rapidly recycle back to the plasma membrane (Tanowitz et al. 2008). Interactions between 
the distal C-tails of mu and delta opioid receptors are important for mu-delta heteromerization 
since reduced mu-delta co-immunoprecipitation is observed in co-transfected Cos cells upon 
truncation of the last 15 C-terminal amino acids of the delta opioid receptor (Fan et al. 2005). 
In addition, reduced co-immunoprecipitation is also observed in vivo in the presence of an 
interfering peptide corresponding to the delta distal C-terminal tail (Kabli et al. 2013). Mu-
delta heteromerization may therefore masks mu MRS, allowing mu opioid receptor sorting to 
the lysosomal compartment.  
 
Activation of endogenous mu-delta heteromers promotes sustained ERK1/2 
phosphorylation  
G protein dependent ERK 1/2 phosphorylation is mediated by βγ dimers and takes place 
shortly after agonist activation (Carmona-Rosas et al. 2018). Accordingly, activation of the 
mu opioid receptor by DAMGO promotes transient pertussis toxin sensitive ERK 1/2 
phosphorylation in transfected HEK293 cells (Massotte et al. 2002). In primary hippocampal 
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neurons, we observed sustained ERK 1/2 phosphorylation following met-enkephalin 
activation of mu-delta heteromers. Pre-treatment with an antagonist for either receptor 
abolished prolonged phosphorylation and receptor co-internalization, strongly supporting mu-
delta specificity and β-arrestin 2 dependent intracellular signalling as described for DAMGO 
(Rozenfeld and Devi 2007). Importantly, rapid transient ERK1/2 phosphorylation by met-
enkephalin is increased upon pre-treatment with a delta antagonist revealing that 
heteromerization dampens mu opioid receptor plasma membrane associated ERK1/2 
phosphorylation by promoting receptor sequestration (Weinberg et al. 2017). This in turn may 
trigger significant changes in the functional response such as reduced nuclear transcriptional 
activation (Eichel and von Zastrow 2018) or decreased activity of GIRK channels (Nagi and 
Pineyro 2014). In the ventral tegmental area where the two receptors functionally interact, 
increased G protein dependent K+ conductance in response to DPDPE or deltorphin II was 
observed in the presence of the mu antagonist CTAP. Conversely the delta antagonist TIPPψ 
enhanced DAMGO evoked responses (Margolis et al. 2017) suggesting that mu-delta 
functional interactions blunt this signalling pathway in vivo.  
Interestingly, heteromerization of the mu opioid and somatostatin sst2 receptors also 
induces sustained β-arrestin 2 dependent ERK1/2 phosphorylation in pancreatic ductal 
adenocarcinoma (Jorand et al. 2016). However, heteromerization of the mu and galanin1 
receptors generates bidirectional negative cross-talk on ERK phosphorylation (Moreno et al. 
2017), indicating that modulation of the ERK pathway varies along with the receptor pair. 
The spatiotemporal control of mu opioid receptor signalling via heteromerization with the 
delta opioid receptor therefore reveals a specific mechanism by which the endogenous opioid 
system can modulate neuronal activity.  
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In vivo functional consequences of mu-delta heteromerization in the RVM 
Association with the delta opioid receptor alters the spatio-temporal dynamics of the mu 
opioid receptor when activated by met-enkephalin and questions the physiological role of mu-
delta heteromers in vivo. Enhanced mu-dependent surface expression of the delta opioid 
receptor in the spinal cord and the dorsal root ganglia is triggered by neuropathic conditions 
((Morinville et al. 2003, Gendron et al. 2006), reviewed in (Gendron et al. 2015)). Here, we 
observed increased mu-delta heteromer expression in the RVM following sciatic nerve 
cuffing that reflects supraspinal adaptation to the pathological condition. Co-expression of 
functional mu and delta opioid receptors in this structure has been described in GABAergic 
interneurons that modulate the descending nociceptive pathway (Pedersen et al. 2011). Mu-
delta targeting to the lysosomal compartment and blunted plasma membrane associated 
ERK1/2 phosphorylation point to decreased mu opioid receptor signalling that would reduce 
the GABAergic inhibitory tonus exerted on the descending nociceptive pathway and suggest 
an antinociceptive role for mu-delta heteromers.  
In a rat model of CFA, functional synergy was observed between DAMGO and the 
delta agonist deltorphin II though no change in receptor expression, affinity or potency could 
be detected in the RVM (Sykes et al. 2007). This synergic effect could be explained by the 
positive cooperativity observed in ligand binding to mu-delta heteromers (Gomes et al. 2011) 
since enkephalins have slightly better affinity for delta opioid receptors (Lord et al. 1977). 
Several lines of evidence indicate a critical role for enkephalin in the RVM besides the well-
established role of peripheral enkephalins in the context of chronic pain (Lesniak and 
Lipkowski 2011). Chronic inflammatory conditions enhance enkephalin expression in the 
RVM (Hurley and Hammond 2001) and microinjection of enkephalin in this structure is 
antinociceptive in a model of inflammatory pain (Little et al. 2012). Also, exercise decreases 
neuropathic pain following sciatic nerve ligation in rat by increasing enkephalin levels in the 
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RVM (Stagg et al. 2011) and i.c.v. injection of the delta antagonist BNTX suppresses 
enkephalin-mediated antinociception (Takemori and Portoghese 1993). Importantly, i.c.v. 
injection of the delta antagonists BNTX or naltriben do not impact β-endorphin 
antinociception suggesting no involvement of the delta opioid receptor in β-endorphin 
mediated effects (Takemori and Portoghese 1993). These findings are in full agreement with 
our observation that enkephalin but not β-endorphin alters mu-delta heteromer function.  
In conclusion, our data demonstrate that mu-delta heteromerization alters the functional 
dynamics of the mu opioid receptor physiological response which provides a way to fine-tune 
mu opioid receptor signalling in pathological conditions. It also represents an interesting 
emerging concept for the development of novel therapeutic drugs and strategies. 
  
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/455147doi: bioRxiv preprint first posted online Oct. 28, 2018; 
 31
Acknowledgments  
The authors would like to thank the Chronobiotron animal facility (UMS 3415 CNRS), and 
the in vitro imaging platform of the Institut des Neurosciences Cellulaires et Intégratives 
(UPS 3156 CNRS) for their assistance. The authors would also like to acknowledge Drs C.M. 
Cahill and I. Gomes for critical reading of the manuscript, and Elisabeth Waltisperger for 
excellent technical contribution.  
The work was performed thanks to the financial support of the Fondation pour la Recherche 
Médicale (DPA20140129364), the CNRS and the University of Strasbourg and, the 
Interdisziplinäres Zentrum für klinische Forschung (Juniorprojekt J61). L. Derouiche was the 
recipient of an IDEX post-doctoral fellowship of the University of Strasbourg. M. Ugur was a 
fellow of the Erasmus Mundus Joint PhD program Neurotime. 
 
Author contributions 
LD, DM, SS designed experiments 
LD, MU, FP, AM, SD, DM, SO conducted experiments and analysed data 
LD, DM, SO wrote the manuscript 
 
 
Declaration of interest 
The authors declare no competing interests.  
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/455147doi: bioRxiv preprint first posted online Oct. 28, 2018; 
 32
References 
Benbouzid, M., V. Pallage, M. Rajalu, E. Waltisperger, S. Doridot, P. Poisbeau, M. J. Freund-
Mercier and M. Barrot (2008). "Sciatic nerve cuffing in mice: a model of sustained 
neuropathic pain." Eur J Pain 12(5): 591-599. 
Benredjem, B., P. Dallaire and G. Pineyro (2017). "Analyzing biased responses of GPCR 
ligands." Curr Opin Pharmacol 32: 71-76. 
Bradbury, F. A., J. C. Zelnik and J. R. Traynor (2009). "G protein independent 
phosphorylation and internalization of the delta-opioid receptor." J Neurochem 109(5): 
1526-1535. 
Carmona-Rosas, G., R. Alcantara-Hernandez and D. A. Hernandez-Espinosa (2018). 
"Dissecting the signaling features of the multi-protein complex GPCR/beta-
arrestin/ERK1/2." Eur J Cell Biol. 
Ceredig, R. A. and D. Massotte (2014). "Fluorescent knock-in mice to decipher the 
physiopathological role of G protein-coupled receptors." Front Pharmacol 5: 289. 
Ceredig, R. A., F. Pierre, S. Doridot, U. Alduntzin, E. Salvat, I. Yalcin, C. Gaveriaux-Ruff, 
M. Barrot and D. Massotte (2018). "Peripheral Delta Opioid Receptors Mediate 
Duloxetine Anti-allodynic Effect in a Mouse Model of Neuropathic Pain." Eur J 
Neurosci. 
Charfi, I., K. Nagi, O. Mnie-Filali, D. Thibault, G. Balboni, P. W. Schiller, L. E. Trudeau and 
G. Pineyro (2014). "Ligand- and cell-dependent determinants of internalization and 
cAMP modulation by delta opioid receptor (DOR) agonists." Cell Mol Life Sci 71(8): 
1529-1546. 
Daniels, D. J., N. R. Lenard, C. L. Etienne, P. Y. Law, S. C. Roerig and P. S. Portoghese 
(2005). "Opioid-induced tolerance and dependence in mice is modulated by the distance 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/455147doi: bioRxiv preprint first posted online Oct. 28, 2018; 
 33
between pharmacophores in a bivalent ligand series." Proc Natl Acad Sci U S A 
102(52): 19208-19213. 
Derouiche, L., S. Ory and D. Massotte (2018). Double fluorescent knock-in mice to 
investigate endogenous mu-delta opioid heteromer subscellular distribution. Receptor-
Receptor Interactions in the Central Nervous System. K. F. a. D. B. Escuela, Springer 
US. 140. 
Doll, C., J. Konietzko, F. Poll, T. Koch, V. Hollt and S. Schulz (2011). "Agonist-selective 
patterns of micro-opioid receptor phosphorylation revealed by phosphosite-specific 
antibodies." Br J Pharmacol 164(2): 298-307. 
Eichel, K. and M. von Zastrow (2018). "Subcellular Organization of GPCR Signaling." 
Trends Pharmacol Sci 39(2): 200-208. 
Erbs, E., L. Faget, R. A. Ceredig, A. Matifas, J. L. Vonesch, B. L. Kieffer and D. Massotte 
(2016). "Impact of chronic morphine on delta opioid receptor-expressing neurons in the 
mouse hippocampus." Neuroscience 313: 46-56. 
Erbs, E., L. Faget, G. Scherrer, A. Matifas, D. Filliol, J. L. Vonesch, M. Koch, P. Kessler, D. 
Hentsch, M. C. Birling, M. Koutsourakis, L. Vasseur, P. Veinante, B. L. Kieffer and D. 
Massotte (2015). "A mu-delta opioid receptor brain atlas reveals neuronal co-
occurrence in subcortical networks." Brain Struct Funct 220(2): 677-702. 
Faget, L., E. Erbs, J. Le Merrer, G. Scherrer, A. Matifas, N. Benturquia, F. Noble, M. 
Decossas, M. Koch, P. Kessler, J. L. Vonesch, Y. Schwab, B. L. Kieffer and D. 
Massotte (2012). "In vivo visualization of delta opioid receptors upon physiological 
activation uncovers a distinct internalization profile." J Neurosci 32(21): 7301-7310. 
Fan, T., G. Varghese, T. Nguyen, R. Tse, B. F. O'Dowd and S. R. George (2005). "A role for 
the distal carboxyl tails in generating the novel pharmacology and G protein activation 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/455147doi: bioRxiv preprint first posted online Oct. 28, 2018; 
 34
profile of mu and delta opioid receptor hetero-oligomers." J Biol Chem 280(46): 38478-
38488. 
Feng, Y., X. He, Y. Yang, D. Chao, L. H. Lazarus and Y. Xia (2012). "Current research on 
opioid receptor function." Curr Drug Targets 13(2): 230-246. 
Fujita, W., I. Gomes and L. A. Devi (2014). "Mu-Delta opioid receptor heteromers: New 
pharmacology and novel therapeutic possibilities." Br J Pharmacol. 
Gaveriaux-Ruff, C. and B. L. Kieffer (2002). "Opioid receptor genes inactivated in mice: the 
highlights." Neuropeptides 36(2-3): 62-71. 
Gendron, L., A. L. Lucido, F. Mennicken, D. O'Donnell, J. P. Vincent, T. Stroh and A. 
Beaudet (2006). "Morphine and pain-related stimuli enhance cell surface availability of 
somatic delta-opioid receptors in rat dorsal root ganglia." J Neurosci 26(3): 953-962. 
Gendron, L., N. Mittal, H. Beaudry and W. Walwyn (2015). "Recent advances on the delta 
opioid receptor: from trafficking to function." Br J Pharmacol 172(2): 403-419. 
Gomes, I., W. Fujita, A. Gupta, S. A. Saldanha, A. Negri, C. E. Pinello, C. Eberhart, E. 
Roberts, M. Filizola, P. Hodder and L. A. Devi (2013). "Identification of a mu-delta 
opioid receptor heteromer-biased agonist with antinociceptive activity." Proc Natl Acad 
Sci U S A 110(29): 12072-12077. 
Gomes, I., A. Gupta, J. Filipovska, H. H. Szeto, J. E. Pintar and L. A. Devi (2004). "A role for 
heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia." 
Proc Natl Acad Sci U S A 101(14): 5135-5139. 
Gomes, I., A. P. Ijzerman, K. Ye, E. L. Maillet and L. A. Devi (2011). "G protein-coupled 
receptor heteromerization: a role in allosteric modulation of ligand binding." Mol 
Pharmacol 79(6): 1044-1052. 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/455147doi: bioRxiv preprint first posted online Oct. 28, 2018; 
 35
Gomes, I., B. A. Jordan, A. Gupta, N. Trapaidze, V. Nagy and L. A. Devi (2000). 
"Heterodimerization of mu and delta opioid receptors: a role in opiate synergy." Journal 
of Neuroscience 20: 1-5. 
Haberstock-Debic, H., K. A. Kim, Y. J. Yu and M. von Zastrow (2005). "Morphine promotes 
rapid, arrestin-dependent endocytosis of mu-opioid receptors in striatal neurons." J 
Neurosci 25(34): 7847-7857. 
Hasbi, A., T. Nguyen, T. Fan, R. Cheng, A. Rashid, M. Alijaniaram, M. M. Rasenick, B. F. 
O'Dowd and S. R. George (2007). "Trafficking of preassembled opioid mu-delta 
heterooligomer-Gz signaling complexes to the plasma membrane: coregulation by 
agonists." Biochemistry 46(45): 12997-13009. 
He, S. Q., Z. N. Zhang, J. S. Guan, H. R. Liu, B. Zhao, H. B. Wang, Q. Li, H. Yang, J. Luo, 
Z. Y. Li, Q. Wang, Y. J. Lu, L. Bao and X. Zhang (2011). "Facilitation of mu-opioid 
receptor activity by preventing delta-opioid receptor-mediated codegradation." Neuron 
69(1): 120-131. 
Henry, A. G., I. J. White, M. Marsh, M. von Zastrow and J. N. Hislop (2011). "The role of 
ubiquitination in lysosomal trafficking of delta-opioid receptors." Traffic 12(2): 170-
184. 
Hislop, J. N., A. G. Henry, A. Marchese and M. von Zastrow (2009). "Ubiquitination 
regulates proteolytic processing of G protein-coupled receptors after their sorting to 
lysosomes." J Biol Chem 284(29): 19361-19370. 
Hurley, R. W. and D. L. Hammond (2001). "Contribution of endogenous enkephalins to the 
enhanced analgesic effects of supraspinal mu opioid receptor agonists after 
inflammatory injury." J Neurosci 21(7): 2536-2545. 
Jorand, R., S. Biswas, D. L. Wakefield, S. J. Tobin, O. Golfetto, K. Hilton, M. Ko, J. W. 
Ramos, A. R. Small, P. Chu, G. Singh and T. Jovanovic-Talisman (2016). "Molecular 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/455147doi: bioRxiv preprint first posted online Oct. 28, 2018; 
 36
signatures of mu opioid receptor and somatostatin receptor 2 in pancreatic cancer." Mol 
Biol Cell 27(22): 3659-3672. 
Just, S., S. Illing, M. Trester-Zedlitz, E. K. Lau, S. J. Kotowski, E. Miess, A. Mann, C. Doll, 
J. C. Trinidad, A. L. Burlingame, M. von Zastrow and S. Schulz (2013). 
"Differentiation of opioid drug effects by hierarchical multi-site phosphorylation." Mol 
Pharmacol 83(3): 633-639. 
Kabli, N., N. Martin, T. Fan, T. Nguyen, A. Hasbi, G. Balboni, B. F. O'Dowd and S. R. 
George (2010). "Agonists at the delta-opioid receptor modify the binding of micro-
receptor agonists to the micro-delta receptor hetero-oligomer." Br J Pharmacol 161(5): 
1122-1136. 
Kabli, N., T. Nguyen, G. Balboni, B. F. O'Dowd and S. R. George (2013). "Antidepressant-
like and anxiolytic-like effects following activation of the mu-delta opioid receptor 
heteromer in the nucleus accumbens." Mol Psychiatry. 
Kouhen, O. M., G. Wang, J. Solberg, L. J. Erickson, P. Y. Law and H. H. Loh (2000). 
"Hierarchical phosphorylation of delta-opioid receptor regulates agonist-induced 
receptor desensitization and internalization." J Biol Chem 275(47): 36659-36664. 
Law, P. Y., L. J. Erickson-Herbrandson, Q. Q. Zha, J. Solberg, J. Chu, A. Sarre and H. H. Loh 
(2005). "Heterodimerization of mu- and delta-opioid receptors occurs at the cell surface 
only and requires receptor-G protein interactions." J Biol Chem 280(12): 11152-11164. 
Law, P. Y., O. M. Kouhen, J. Solberg, W. Wang, L. J. Erickson and H. H. Loh (2000). 
"Deltorphin II-induced rapid desensitization of delta-opioid receptor requires both 
phosphorylation and internalization of the receptor." J Biol Chem 275(41): 32057-
32065. 
Lesniak, A. and A. W. Lipkowski (2011). "Opioid peptides in peripheral pain control." Acta 
Neurobiol Exp (Wars) 71(1): 129-138. 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/455147doi: bioRxiv preprint first posted online Oct. 28, 2018; 
 37
Little, J. W., Z. Chen, T. Doyle, F. Porreca, M. Ghaffari, L. Bryant, W. L. Neumann and D. 
Salvemini (2012). "Supraspinal peroxynitrite modulates pain signaling by suppressing 
the endogenous opioid pathway." J Neurosci 32(32): 10797-10808. 
Lord, J. A., A. A. Waterfield, J. Hughes and H. W. Kosterlitz (1977). "Endogenous opioid 
peptides: multiple agonists and receptors." Nature 267(5611): 495-499. 
Margolis, E. B., W. Fujita, L. A. Devi and H. L. Fields (2017). "Two delta opioid receptor 
subtypes are functional in single ventral tegmental area neurons, and can interact with 
the mu opioid receptor." Neuropharmacology 123: 420-432. 
Massotte, D. (2015). "In vivo opioid receptor heteromerization: where do we stand?" Br J 
Pharmacol 172(2): 420-434. 
Massotte, D., K. Brillet, B. L. Kieffer and G. Milligan (2002). "Agonists activate Gi1a or Gi2a 
fused to the human mu opioid receptor differently." Journal of Neurochemistry 81: 
1372-1382. 
Milan-Lobo, L. and J. L. Whistler (2011). "Heteromerization of the mu- and delta-opioid 
receptors produces ligand-biased antagonism and alters mu-receptor trafficking." J 
Pharmacol Exp Ther 337(3): 868-875. 
Minnis, J. G., S. Patierno, S. E. Kohlmeier, N. C. Brecha, M. Tonini and C. Sternini (2003). 
"Ligand-induced mu opioid receptor endocytosis and recycling in enteric neurons." 
Neuroscience 119(1): 33-42. 
Moreno, E., C. Quiroz, W. Rea, N. S. Cai, J. Mallol, A. Cortes, C. Lluis, E. I. Canela, V. 
Casado and S. Ferre (2017). "Functional mu-Opioid-Galanin Receptor Heteromers in 
the Ventral Tegmental Area." J Neurosci 37(5): 1176-1186. 
Morinville, A., C. M. Cahill, M. J. Esdaile, H. Aibak, B. Collier, B. L. Kieffer and A. Beaudet 
(2003). "Regulation of delta-opioid receptor trafficking via mu-opioid receptor 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/455147doi: bioRxiv preprint first posted online Oct. 28, 2018; 
 38
stimulation: evidence from mu-opioid receptor knock-out mice." J Neurosci 23(12): 
4888-4898. 
Nagi, K. and G. Pineyro (2014). "Kir3 channel signaling complexes: focus on opioid receptor 
signaling." Front Cell Neurosci 8: 186. 
Ong, E. W., L. Xue, M. C. Olmstead and C. M. Cahill (2015). "Prolonged morphine treatment 
alters delta opioid receptor post-internalization trafficking." Br J Pharmacol 172(2): 
615-629. 
Pedersen, N. P., C. W. Vaughan and M. J. Christie (2011). "Opioid receptor modulation of 
GABAergic and serotonergic spinally projecting neurons of the rostral ventromedial 
medulla in mice." J Neurophysiol 106(2): 731-740. 
Pradhan, A. A., J. A. Becker, G. Scherrer, P. Tryoen-Toth, D. Filliol, A. Matifas, D. Massotte, 
C. Gaveriaux-Ruff and B. L. Kieffer (2009). "In vivo delta opioid receptor 
internalization controls behavioral effects of agonists." PLoS ONE 4(5): e5425. 
Qiu, Y., P. Y. Law and H. H. Loh (2003). "Mu-opioid receptor desensitization: role of 
receptor phosphorylation, internalization, and representation." J Biol Chem 278(38): 
36733-36739. 
Qiu, Y., H. H. Loh and P. Y. Law (2007). "Phosphorylation of the delta-opioid receptor 
regulates its beta-arrestins selectivity and subsequent receptor internalization and 
adenylyl cyclase desensitization." J Biol Chem 282(31): 22315-22323. 
Rozenfeld, R., N. S. Abul-Husn, I. Gomez and L. A. Devi (2007). "An emerging role for the 
delta opioid receptor in the regulation of mu opioid receptor function." 
ScientificWorldJournal 7: 64-73. 
Rozenfeld, R. and L. A. Devi (2007). "Receptor heterodimerization leads to a switch in 
signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor 
heterodimers." Faseb J 21(10): 2455-2465. 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/455147doi: bioRxiv preprint first posted online Oct. 28, 2018; 
 39
Salvadori, S., R. Guerrini, G. Balboni, C. Bianchi, S. D. Bryant, P. S. Cooper and L. H. 
Lazarus (1999). "Further studies on the Dmt-Tic pharmacophore: hydrophobic 
substituents at the C-terminus endow delta antagonists to manifest mu agonism or mu 
antagonism." J Med Chem 42(24): 5010-5019. 
Scherrer, G., P. Tryoen-Toth, D. Filliol, A. Matifas, D. Laustriat, Y. Q. Cao, A. I. Basbaum, 
A. Dierich, J. L. Vonesh, C. Gaveriaux-Ruff and B. L. Kieffer (2006). "Knockin mice 
expressing fluorescent delta-opioid receptors uncover G protein-coupled receptor 
dynamics in vivo." Proc Natl Acad Sci U S A 103(25): 9691-9696. 
Skieterska, K., P. Rondou and K. Van Craenenbroeck (2017). "Regulation of G Protein-
Coupled Receptors by Ubiquitination." Int J Mol Sci 18(5). 
Stagg, N. J., H. P. Mata, M. M. Ibrahim, E. J. Henriksen, F. Porreca, T. W. Vanderah and T. 
Philip Malan, Jr. (2011). "Regular exercise reverses sensory hypersensitivity in a rat 
neuropathic pain model: role of endogenous opioids." Anesthesiology 114(4): 940-948. 
Sykes, K. T., S. R. White, R. W. Hurley, H. Mizoguchi, L. F. Tseng and D. L. Hammond 
(2007). "Mechanisms responsible for the enhanced antinociceptive effects of micro-
opioid receptor agonists in the rostral ventromedial medulla of male rats with persistent 
inflammatory pain." J Pharmacol Exp Ther 322(2): 813-821. 
Takemori, A. E. and P. S. Portoghese (1993). "Enkephalin antinociception in mice is 
mediated by delta 1- and delta 2-opioid receptors in the brain and spinal cord, 
respectively." Eur J Pharmacol 242(2): 145-150. 
Tanowitz, M., J. N. Hislop and M. von Zastrow (2008). "Alternative splicing determines the 
post-endocytic sorting fate of G-protein-coupled receptors." J Biol Chem 283(51): 
35614-35621. 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/455147doi: bioRxiv preprint first posted online Oct. 28, 2018; 
 40
Tanowitz, M. and M. von Zastrow (2003). "A novel endocytic recycling signal that 
distinguishes the membrane trafficking of naturally occurring opioid receptors." J Biol 
Chem 278(46): 45978-45986. 
Thompson, G. L., J. R. Lane, T. Coudrat, P. M. Sexton, A. Christopoulos and M. Canals 
(2016). "Systematic analysis of factors influencing observations of biased agonism 
at the mu-opioid receptor." Biochem Pharmacol 113: 70-87. 
Trafton, J. A., C. Abbadie, K. Marek and A. I. Basbaum (2000). "Postsynaptic signaling via 
the [mu]-opioid receptor: responses of dorsal horn neurons to exogenous opioids 
and noxious stimulation." J Neurosci 20(23): 8578-8584. 
Wang, D., V. L. Tawfik, G. Corder, S. A. Low, A. François, A. I. Basbaum and G. Scherrer 
(2018). "Functional divergence of delta and mu opioid receptro organization in 
CNS pain circuits." Neuron 98. 
Weinberg, Z. Y., A. S. Zajac, T. Phan, D. J. Shiwarski and M. A. Puthenveedu (2017). 
"Sequence-Specific Regulation of Endocytic Lifetimes Modulates Arrestin-Mediated 
Signaling at the micro Opioid Receptor." Mol Pharmacol 91(4): 416-427. 
Xie, W. Y., Y. He, Y. R. Yang, Y. F. Li, K. Kang, B. M. Xing and Y. Wang (2009). "Disruption of 
Cdk5-associated phosphorylation of residue threonine-161 of the delta-opioid 
receptor: impaired receptor function and attenuated morphine antinociceptive 
tolerance." J Neurosci 29(11): 3551-3564. 
Yalcin, I., S. Megat, F. Barthas, E. Waltisperger, M. Kremer, E. Salvat and M. Barrot (2014). 
"The sciatic nerve cuffing model of neuropathic pain in mice." J Vis Exp 89: e51608. 
Yousuf, A., E. Miess, S. Sianati, Y. P. Du, S. Schulz and M. J. Christie (2015). "Role of 
Phosphorylation Sites in Desensitization of micro-Opioid Receptor." Mol 
Pharmacol 88(4): 825-835. 
  
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/455147doi: bioRxiv preprint first posted online Oct. 28, 2018; 
 41
 
Figure legends  
 
Figure 1: Mu and delta opioid receptors co-internalize upon CYM51010 activation in 
primary hippocampal cultures 
 A) Representative confocal images showing mu-mCherry and delta-eGFP fluorescence 
localized at the plasma membrane (arrowheads) under basal condition or internalized in 
vesicle-like structures 15 or 60 minutes after CYM51010 (400nM) application (arrows). Scale 
bar = 10μm. 
B) Receptor internalization induced by CYM51010 application (400nM) expressed as a 
ratio of membrane-associated versus intracellular fluorescence densities for each receptor. 
Two-way ANOVA Ftreatment (3;94)=17.98 ; p-value <0.0001. Freceptor (1; 94)=1.06; 
Finteraction (3; 94)=0.54. Tukey’s post-hoc test for mu-mCherry ***: p <0.001; **: p = 0.01.  
Tukey’s post-hoc test for delta-eGFP *:p = 0.02 ; **:p = 0.002 ; ***:p < 0.001.  N=10 to 20 
neurons per group from at least 3 independent cultures 
C) Subcellular redistribution of mu-delta heteromers expressed as a ratio of membrane-
associated versus intracellular fluorescence densities for co-localized mu-mCherry and delta-
eGFP receptors. One-way ANOVA (F (3,48) = 13.64; p < 0.0001) followed with multiple 
comparisons Dunn’s post hoc test. *:p = 0.03 ;  ***:p <0.001. N=10 to 20 neurons per group 
from at least 3 independent cultures. 
D) Fraction of cytoplasmic mu-delta heteromers expressed as the percentage of mu-
mCherry and delta-eGFP overlapping objects detected in vesicle-like structures at the 
different time points. Kruskal Wallis test (p < 0.0001) followed with multiple comparisons 
Dunn’s post hoc test. **:p = 0.004 ; ***:p <0.001. N=10 to 20 neurons per group from at least 
3 independent cultures. 
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Figure 2: Mu and delta opioid receptors co-localize in the lysosomal compartment upon 
CYM51010 activation in primary hippocampal cultures 
A) Representative confocal images showing mu-mCherry-delta-eGFP colocalization 
with LAMP1 immunoreactive compartment under basal condition or 60 minutes after 
CYM51010 application (400nM). Scale bar = 10μm (inset scale bar = 2.5 μm). 
B) Drug treatment induces statistically significant increase in the amount of 
colocalization of mu-mCherry / delta-eGFP colocalization with LAMP1 labeling. Two-way 
ANOVA Fdrug treatment (1; 49)=62.70 ; p < 0.0001. Freceptor (1; 49) = 2.12, p = 0.15 ; 
Finteraction (1; 49)=3.65, p = 0.2.  Tukey’s post hoc test: ***p < 0.001 for both mu-mCherry 
and delta-eGFP.  N=10 to 20 neurons per group from at least 3 independent cultures. 
 
Figure 3: CYM51010 internalization of mu or delta opioid receptors in primary 
hippocampal cultures from mice deficient for one of the receptors   
A) Representative confocal images showing that mu-mCherry is associated with the 
plasma membrane (arrows) in basal conditions and 30 minutes after CYM51010 (400nM) 
addition in delta-KO mice. Scale bar = 10μm 
B) Mu-mCherry internalization induced by CYM51010 application expressed as a ratio 
of membrane-associated versus intracellular fluorescence densities. Mann-Whitney test, p 
=0.20. N=13 to 20 neurons per group from at least 3 independent cultures. 
C) Representative confocal images showing that delta-eGFP is predominantly 
associated with the plasma membrane in basal conditions (arrows) in mu-KO mice whereas 
the association is mostly intracellular at 30 and 60 minutes after CYM51010 (400nM) 
addition (arrowheads). Scale bar = 10μm 
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D) Delta-eGFP internalization induced by CYM51010 application expressed as a ratio 
of membrane-associated versus intracellular fluorescence densities. Kruskal-Wallis test (p 
<0.0001) followed by Dunn’s multiple comparison test Significant differences after multiple 
comparisons tests are expressed as p <0.001(***) compared to basal group. N=9-20 neurons 
per group from at least 3 independent cultures. 
 
Figure 4: Antagonist pre-treatment abolishes mu-delta opioid receptor co-
internalization by CYM51010 in primary hippocampal cultures 
A) Representative confocal images showing mu-mCherry predominant localization at 
the plasma membrane and delta-eGFP extensive internalization after pre-treatment with the 
mu antagonist β-FNA (200nM) for 15 minutes followed by incubation for 60 minutes with 
CYM51010 (400nM). Scale bar = 10μm. 
B) Representative confocal images showing mu-mCherry and delta-eGFP predominant 
localization at the plasma membrane after pre-treatment with delta antagonist naltrindole 
(200nM) (NTI) for 15minutes followed by incubation for 60 minutes with CYM51010 
(400nM). Scale bar = 10μm. 
C) Pre-treatment with the mu antagonists β-FNA or CTAP (200nM) blocks mu-
mCherry but not delta-eGFP internalization, whereas pre-treatment with the delta antagonists 
naltrindole (NTI) and Tic-deltorphin (tic) (200nM) prevent internalization of both mu-
mCherry and delta-eGFP. Receptor internalization is expressed as a ratio of membrane-
associated versus intracellular fluorescence densities for each receptor. Two-way ANOVA F
 
treatment (5;104)=4.73 ; p =0.0001. Freceptor (1; 104)=0.1; p= 0.84 ; Finteraction (5; 100)=1.96; 
p = 0.0006. Multiple comparisons with Tukey’s posthoc test *p=0.04 basal vs CYM51010 for 
mu-mCherry, *p=0.04 basal vs CYM51010, *p =0.04, basal vs β-FNA, *p = 0.04, basal vs 
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CTAP, **p = 0.006. for delta-eGFP. N=9 to 20 neurons per group from at least 3 independent 
cultures. 
D) Mu-mCherry/delta-eGFP co-internalization is prevented by treatment with either mu 
or delta antagonists. Percentage of colocalized receptors in the cytoplasm after drug treatment. 
The fraction of cytoplasmic mu-delta heteromers is expressed as the percentage of mu-
mCherry and delta-eGFP overlapping objects detected in vesicle-like structures 60 minutes 
after CYM51010 application. One-way ANOVA (p<0.0001) followed by multiple 
comparisons Dunnett’s test. Significant differences after multiple comparisons tests are 
expressed as ***p<0.001 when compared to basal group and ###p<0.001 when compared to 
CYM51010 without antagonists. N=9 to 20 neurons per group from at least 3 independent 
cultures. 
 
Figure 5: Agonist-induced in vivo phosphorylation of mu and delta opioid receptors  
A) Representative Western blot showing the phosphorylation of the delta opioid 
receptor at the C-terminal serine 363 residue upon by CYM51010 (10mg/kg i.p,), SNC80 
(10mg/kg i.p.) or Met-enkephalin (375 nmol i.c.v.) in vivo administration in double 
fluorescent knock-in mice (delta-eGFP/mu-mCherry) or in mice only expressing the 
fluorescent delta opioid receptor (delta-eGFP/mu KO). 
B) Representative Western blot showing the phosphorylation of the mu opioid receptor 
at specific C-terminal residues upon CYM51010 (10mg/kg i.p,), fentanyl (0.3mg/kg i.p.) or 
Met-enkephalin (375 nmol i.c.v.) in vivo administration in double fluorescent knock-in mice 
(delta-eGFP/mu-mCherry) or in mice only expressing the fluorescent mu opioid receptor (mu-
mCherry/delta KO). 
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Figure 6: Mu-delta opioid receptor co-internalization is ligand selective in primary 
hippocampal cultures 
Representative confocal images showing mu-mCherry and delta-eGFP fluorescence at 
the plasma membrane (arrowheads) under basal conditions or co-internalized in vesicle-like 
structures (arrows) 30 minutes after DAMGO (1 μM) or deltorphin II (100nM) but not 
SNC80 (100nM). Scale bar =10μm. 
 
Figure 7: Met-enkephalin internalization of mu or delta opioid receptors expressed 
alone 
A) Representative confocal images showing mu-mCherry fluorescence mainly localized 
at the plasma membrane under basal conditions or internalized in vesicle-like structures 30 
minutes after Met-enkephalin challenge (100nM). 60 minutes, mu-mCherry was mainly 
detected back at the plasma membrane. Scale bar = 10μm. 
B) Quantification of mu-mCherry internalization expressed as a ratio of membrane-
associated versus intracellular fluorescence densities. Kruskal-Wallis test (p <0.0001) 
followed by Dunn’s multiple comparison test p<0.001(***) compared to basal group. n=10 to 
19 neurons per group from at least  3 independent cultures. 
C) Representative confocal images showing delta-eGFP fluorescence mainly localized 
at the plasma membrane under basal conditions or internalized in vesicle-like structures 30 or 
60 minutes after Met-enkephalin challenge (100nM). Scale bar = 10μm. 
D) Quantification of delta-eGFP internalization expressed as a ratio of membrane-
associated versus intracellular fluorescence densities. Kruskal-Wallis test (p <0.0001) 
followed by Dunn’s multiple comparison test. p=0.002(**) compared to basal group. n=13 to 
20 neurons per group from at least 3 independent cultures. 
 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/455147doi: bioRxiv preprint first posted online Oct. 28, 2018; 
 46
Figure 8: Mu and delta opioid receptors co-internalize upon met-enkephalin activation 
in primary hippocampal cultures 
A) Representative confocal images showing mu-mCherry and delta-eGFP subcellular 
localization. In basal conditions, receptors are predominantly co-localized (inset arrows) at 
the periphery of the neuron (top panel). Following 100nM Met-enkephalin application for 15, 
30, 60 minutes, receptors are co-internalized and co-localize in the cytoplasm (inset arrows). 
Scale bar = 10 μm (inset scale bar = 5 μm). 
B) Receptor internalization induced by met-enkephalin application (100nM) expressed 
as a ratio of membrane-associated versus intracellular fluorescence densities for each 
receptor. Two-way ANOVA Fdrug treatment (3;105)=34.54 ; p <0.0001. Freceptor (1; 
105)=1.27 ; Finteraction (3; 105)=0.08. Multiple comparisons were made with Tukey’s test, 
***: p <0.001. N=12 to 19 neurons per group from at least 3 independent cultures. 
C) Subcellular redistribution of mu-delta heteromers expressed as a ratio of membrane-
associated versus intracellular fluorescence densities for co-localized mu-mCherry and delta-
eGFP receptors. Kruskal Wallis test (p < 0.0001) followed with multiple comparisons Dunn’s 
test. ** p <0.01 ; ***p <0.001. N=12 to 19 neurons per group from at least 3 independent 
cultures.  
D) Fraction of cytoplasmic mu-delta heteromers expressed as the percentage of mu-
mCherry and delta-eGFP overlapping objects detected in vesicle-like structures at the 
different times. Kruskal Wallis test (p < 0.0001) followed with multiple comparisons Dunn’s 
test. p = 0.28 15 min vs basal, p = 0.09, 30 min vs basal, ***p < 0.0001 60 min vs basal. 
N=12 to 19 neurons per group from at least 3 independent cultures. 
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Figure 9: Mu and delta opioid receptors co-localize in the lysosomal compartment upon 
met-enkephalin activation in primary hippocampal cultures  
A) Representative confocal images showing mu-mCherry-delta-eGFP colocalization 
with LAMP1 immunoreactive compartments under basal condition or 60 minutes after Met-
enkephalin (100nM) application. Scale bar = 10 μm (Inset Scale bar = 2.5 μm). 
 
B) Met-enkephalin induces statistically significant increases in the amount of mu-
mCherry / delta-eGFP colocalization with LAMP1 labeling. Two-way ANOVA Fdrug 
treatment (1;59)=123.5 ; P < 0.0001. Freceptor (1; 59) = 4.04, p-value = 0.05 ; Finteraction (1; 
59)=3.08, p-value = 0.08.  Tukey’s multiple comparisons: ***p < 0.0001 for both mu-
mCherry and delta-eGFP.  N=12 to 16 neurons per group from at least 3 independent cultures. 
 
Figure 10: Antagonist pre-treatment abolishes mu-delta opioid receptor co-
internalization by met-enkephalin in primary hippocampal cultures 
A) Representative confocal images showing mu-mCherry predominant localization at 
the membrane and delta-eGFP extensive internalization following met-enkephalin (100nM) 
incubation for 60 minutes in primary neurons pretreated with the mu antagonist β-FNA 200 
nM for 15 minutes. Scale bar = 10μm. 
B) Representative confocal images showing mu-mCherry and delta-eGFP predominant 
localization at the membrane following met-enkephalin incubation for 60 minutes in primary 
neurons pretreated with the delta antagonist naltrindole (NTI) (200nM) for 15 minutes Scale 
bar = 10μm.  
C) Quantification of mu or delta opioid receptor internalization respectively, expressed 
as a ratio of receptor density in the membrane versus mu or delta mu-mCherry or delta-eGFP 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/455147doi: bioRxiv preprint first posted online Oct. 28, 2018; 
 48
receptor density in the cytoplasm. Pre-treatment with the mu selective antagonists β-FNA (20 
nM) or CTAP (200nM) blocks mu-mCherry but not delta-eGFP internalization following 
met-enkephalin application. Pre-treatment with the delta selective antagonists NTI or Tic-
deltorphin (200nM) blocks met-enkephalin-induced internalization of both mu-mCherry and 
delta-eGFP. Two-way ANOVA Fdrug treatment (5;100)=6.38 ; p <0.0001. Freceptor (1; 
100)=3.96; p= 0.04 ; Finteraction (5; 100)=1.97; p = 0.09. N=10 to 12 neurons per group from 
at least 3 independent experiments. 
D) Mu-delta co-internalization is prevented by treatment with either mu or delta 
selective antagonists. Percentage of co-localized receptors in the cytoplasm after drug 
treatment. The fraction of cytoplasmic mu-delta heteromers is expressed as the percentage of 
mu-mCherry and delta-eGFP overlapping objects detected in vesicle-like structures 60 
minutes after CYM51010 application. Kruskal Wallis test (p = 0.0001) followed by multiple 
comparisons Dunn’s test. Significant differences after multiple comparisons tests are 
expressed as ***, p < 0.001when compared to basal group and ###, p < 0.001 when compared 
to Met-enkephalin without antagonists. N=10 to 12 neurons per group from at least 3 
independent cultures. 
 
Figure 11: Mu and delta opioid receptors co-localize in the lysosomal compartment upon 
Met-enkephalin activation in vivo 
A) Representative confocal images showing mu-mCherry and delta-eGFP co-
localization with LAMP1 immunoreactive compartment in the hippocampus under basal 
condition or 60 minutes after Met-enkephalin (100nM) application. Scale bar = 10μm. 
B) Receptor internalization induced by Met-enkephalin injection (375 nmoles i.c.v.) 
expressed as a ratio of membrane-associated versus intracellular fluorescence densities for 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/455147doi: bioRxiv preprint first posted online Oct. 28, 2018; 
 49
each receptor. Student’s unpaired t-test, **p = 0.003 for mu-mCherry, ***p = 0.001 for delta-
eGFP. N=17 to 25 neurons per group from at least 3 mice. 
C) Mu-delta heteromers expressed as the percentage of mu-mCherry and delta-eGFP 
overlapping objects detected at the plasma membrane or in the cytoplasm in basal conditions 
Student’s unpaired t-test test (p > 0.05) N=17 to 25 neurons per group from at least 3 mice. 
D) Met-enkephalin increases the amount of mu-mCherry / delta-eGFP co-localization 
with LAMP1 labeling after 60 minutes. Student’s unpaired t-test test. N=18 neurons per group 
from at least 3 mice.  
 
Figure 12: Mu and delta opioid receptors do not co-internalize upon β-endorphin 
activation in primary hippocampal cultures 
A) Representative confocal images showing mu-mCherry and delta-eGFP subcellular 
localization. In basal conditions receptors are predominantly co-localized (arrowheads) at the 
surface of the neuron. Upon activation with β-endorphin (100nM), receptors are internalized 
(arrows) but no significant co-localization can be detected. Moreover, mu-mCherry is 
detectable at the plasma membrane after 60 minutes (arrowheads). Scale bar = 10μm. 
B) Quantification of internalization given as a ratio of mu-mCherry  or delta-eGFP 
receptor density in the membrane relative to the density in the cytoplasm. Two-way ANOVA 
F
 treatment (3; 123) = 9.61 ; p-value <0.0001. Freceptor (1; 123)=2.20, p-value= 0.19 ; 
Finteraction (3; 123)=0.55, p-value=0.20. Multiple comparisons were made with Tukey’s test. 
For Mu-mCherry: *** p < 0.001 15 min vs basal, p = 0.15 30 min vs basal; p = 0.11 60 min 
vs basal. ## p = 0.03 30 min vs 15 min; # p = 0.04 60 min vs 15 min.  For Delta-eGFP: ***p 
= 0.001 15min vs basal, *p = 0.02 30 min vs basal, ***p = 0.001 60 min vs basal. N=10 to 20 
neurons per group from at least 3 independent cultures. 
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C) Subcellular redistribution of mu-delta heteromers expressed as a ratio of membrane-
associated versus intracellular fluorescence densities for co-localized mu-delta opioid 
receptors. Kruskal Wallis test (p = 0.21) followed with multiple comparisons Dunn’s test. 
NS= No statistically significant differences (p = 0.27 15 min vs basal, p = 0.94 30 min vs 
basal, p = 0.86 60min vs basal). N=10 to 20 neurons per group from at least 3 independent 
experiments.  
D) Fraction of cytoplasmic mu-delta heteromers expressed as a percentage of mu-
mCherry and delta-eGFP overlapping objects detected in vesicle-like structures at the 
different time points. Kruskal Wallis test (p = 0.51) followed with multiple comparisons 
Dunn’s test. NS= No statistically significant differences (p = 0.47 15 min vs basal, p = 0.99 
30 min or 60 min vs basal). N=10 to 20 neurons per group from at least 3 independent 
cultures. 
 
Figure 13: Mu-delta heteromerization alters met-enkephalin induced kinetics of  
ERK1/2 phosphorylation in primary hippocampal cultures  
A) Primary hippocampal cultures were treated with DAMGO (1μM), CYM51010 
(400nM), Met-enkephalin (100nM) or β-endorphin (100nM) for the indicated time. 
Representative Western blot with phosphorylated ERK1/2 (pERK1/2) and total ERK1/2 
antibody (left panel) and quantification (right panel). At least three independent experiments 
were performed for each condition.  
B) Primary hippocampal cultures were treated with met-enkephalin (100nM) alone or in 
combination with CTAP (200nM) or Tic-deltorphin (200nM) for the indicated time. 
Representative Western blot with phosphorylated ERK1/2 (pERK1/2) and total ERK1/2 
antibody (left panel) and quantification from at least three independent experiments were 
performed for each condition (right panel). Two-way ANOVA Ftime (5, 41)=2.844, p-
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value=0.27. Ftreatment (2, 41)=0.844, p= 0.438; Finteraction (10, 41)=2.344, p =0.271. Tukey 
post hoc test. ** p =0.0082, * p =0.029. 
 
Figure 14:  Mu-delta heteromer expression is increased in the rostral ventromedial 
medulla in neuropathic conditions 
A) Representative confocal images showing mu-mCherry and delta-eGFP neuronal co-
localization in the RVM in sham and neuropathic conditions. Scale bar= 50μm 
B) Quantification of the density of neurons co-expressing mu and delta opioid receptors. 
N=3 mice par condition. Unpaired Student’s t test, **p value=0.0097. 
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